Loading
Leucid Bio is a London company, spun out of King's College London, that re-engineers CAR-T cells, a patient's own immune cells modified to find cancer, so that they work against solid tumours. Its first product, LEU011, is in an early trial.
Leucid Bio, headquartered in London with operations at Guy's Hospital, was founded in 2014, according to the company, to translate CAR-T research led by John Maher at King's College London. Its Lateral CAR platform redesigns the receptor so that signalling domains are distributed laterally, as in natural immune receptors. The lead product LEU011 is an NKG2D-targeting lateral CAR-T therapy given as a single intravenous dose after preconditioning chemotherapy, and the company is also developing an in vivo programme with Syenex. It raised GBP 11.5 million in a Series A in 2021, and names Epidarex, 2Invest, Sofinnova Partners, Vulpes Investment Management and the Future Fund of the British Business Bank as investors. Its first registered cancer trial, NCT06193902 (AERIAL), a phase 1/2a dose-escalation study of LEU011 in relapsed or refractory solid tumours in London and Manchester, was posted on ClinicalTrials.gov in January 2024; the registry gives its start as November 2023.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · GBP 11.5 million, as stated on the company website | 2021 | undisclosed | leucid.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/